期刊
MOLECULAR NEUROBIOLOGY
卷 58, 期 1, 页码 281-303出版社
SPRINGER
DOI: 10.1007/s12035-020-02116-9
关键词
Alzheimer's disease; Multi-target drugs; Multi-target-directed ligands; AChE; NMDAR
资金
- Deanship of Scientific Research at Princess Nourah bint Abdulrahman University through the Fast-Track Research Funding Program
- King Saud University, Deanship of Scientific Research, College of Science Research Center
Alzheimer's disease is a common form of dementia in elderly people, with approved medications including ChEIs and NMDAR antagonists. Single-target therapies have shown to be unsuccessful in treating the multifactorial symptoms or disease progression of Alzheimer's, highlighting the need for diverse pharmacological targets in treatment.
Alzheimer's disease (AD) is one of the most common forms of dementia among elder people, which is a progressive neurodegenerative disease that results from a chronic loss of cognitive activities. It has been observed that AD is multifactorial, hence diverse pharmacological targets that could be followed for the treatment of AD. The Food and Drug Administration has approved two types of medications for AD treatment such as cholinesterase inhibitors (ChEIs) andN-methyl-d-aspartic acid receptor (NMDAR) antagonists. Rivastigmine, donepezil, and galantamine are the ChEIs that have been approved to treat AD. On the other hand, memantine is the only non-competitive NMDAR antagonist approved in AD treatment. As compared with placebo, it has been revealed through clinical studies that many single-target therapies are unsuccessful to treat multifactorial Alzheimer's symptoms or disease progression. Therefore, due to the complex nature of AD pathophysiology, diverse pharmacological targets can be hunted. In this article, based on the entwined link of acetylcholinesterase (AChE) and NMDAR, we represent several multifunctional compounds in the rational design of new potential AD medications. This review focus on the significance of privileged scaffolds in the generation of the multi-target lead compound for treating AD, investigating the idea and challenges of multi-target drug design. Furthermore, the most auspicious elementary units for designing as well as synthesizing hybrid drugs are demonstrated as pharmacological probes in the rational design of new potential AD therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据